Skip to content
  • Tuesday, 29 September 2026
  • 3:40 pm
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • BioMarin Pharmaceutical Finalizes $4.8 Billion Acquisition of Amicus Therapeutics, Bolstering Rare Disease Portfolio
Pharmaceutical R&D

BioMarin Pharmaceutical Finalizes $4.8 Billion Acquisition of Amicus Therapeutics, Bolstering Rare Disease Portfolio

Teuku Ryan Apr 29, 2026 0

BioMarin Pharmaceutical has officially concluded its substantial acquisition of Amicus Therapeutics, a move that promises to significantly expand BioMarin’s footprint…

Read More
Science News: A Century of Empowering Public Understanding of ScienceUnlocking Evolutionary Accelerators: Flipped DNA Segments Drive Rapid Speciation in Cichlid FishUniversity of Georgia Researchers Officially Describe Two Previously Unknown Black Bass Species: Bartram’s Bass and Altamaha BassResetting the Internal Clock: New Research Suggests Circadian Rhythms are Vital to Stroke Recovery
Japan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactThe Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals PlummetMEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric GrowthLLMOps in 2026: The 10 Tools Every Team Must Have
Tolerance Bio Secures Exclusive Global Rights Outside Japan for Tanabe Pharma Anti-IL-33 Monoclonal Antibody TLB-33 in Landmark $560m DealUnprecedented Genetic Study Reveals Explosive Growth Rates and Origins of Chronic Myeloid Leukemia Years Before DiagnosisAs the dream of the autonomous clinical trial dawns, agent supervision is today’s human jobNew Research Identifies Peripheral Immune Pathway as a Critical Driver of Alzheimer’s Disease Neurodegeneration
YOU MAY HAVE MISSED
Pharmaceutical R&D
Tolerance Bio Secures Exclusive Global Rights Outside Japan for Tanabe Pharma Anti-IL-33 Monoclonal Antibody TLB-33 in Landmark $560m Deal
Teuku Ryan Sep 29, 2026
Stem Cell & Regenerative Medicine
Unprecedented Genetic Study Reveals Explosive Growth Rates and Origins of Chronic Myeloid Leukemia Years Before Diagnosis
Dwi Wanna Sep 29, 2026
Laboratory Automation & Robotics
As the dream of the autonomous clinical trial dawns, agent supervision is today’s human job
Lana Keisha Sep 29, 2026
Neuroscience & Brain Research
New Research Identifies Peripheral Immune Pathway as a Critical Driver of Alzheimer’s Disease Neurodegeneration
Rifan Muazin Sep 29, 2026

Copyright © 2026 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ